U.S. markets close in 20 minutes

Cryoport, Inc. (CYRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
23.26-0.84 (-3.49%)
As of 03:40PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close24.10
Bid23.27 x 1000
Ask23.33 x 1100
Day's Range23.17 - 24.10
52 Week Range15.63 - 45.36
Avg. Volume474,281
Market Cap1.14B
Beta (5Y Monthly)1.31
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CYRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CryoPort, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • PR Newswire

    Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies

    Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences industry focused on the pharmaceutical and cell and gene therapy markets, today announced a new strategic partnership with Syneos Health® (NASDAQ: SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. Both Cryoport and Syneos Health are world leading solutions companies with deep ex

  • PR Newswire

    Cryoport to Present at the J.P. Morgan 41st Annual Healthcare Conference

    Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Jerrell Shelton, the Company's Chief Executive Officer, will be presenting at the J.P. Morgan 41st Annual Healthcare conference, taking place from January 9 - 12, 2023 in San Francisco, CA. Mr. Shelton will be presenting on Thursday, January 12, 2023, at 8:15 a.m. PT (11:15 a.m. ET). Additionally, Mr. Shelton, Robert St

  • PR Newswire

    Cryoport Reports Results for the Third Quarter 2022

    Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and nine-month periods ended September 30, 2022.